TARDBP and amyotrophic lateral sclerosis: With these studies we demonstrated the efficacy of two antibody-based approaches againstthe RRM1-domain of TDP-43 in reducing the intracellular TDP-43 proteinopathy and rescuingdeficits in ALS/ FTLD mouse models.